Clinical Trial

Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the preliminary efficacy of single SC administration of MBX 1416 at different dose levels in patients with PBH
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-06-18; most recent amendment 2026-06-30.
Status change: Recruiting → Completed 2026-06-30
Status change: Not Yet Recruiting → Recruiting 2025-09-25
Trial Details
NCT Number NCT07029412
Lead Sponsor MBX Biosciences
Conditions Postbariatric Hypoglycemia
Enrollment 20 participants
Start Date 2025-08-26
Primary Completion 2026-04-18 (estimated)
Study Completion 2026-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-02